NOEL

IAR Systems and CAES improve embedded tech in space

Retrieved on: 
Thursday, December 15, 2022
IAR, Software, CAES, IAR Systems, Ecosystem, Name, NOEL, Partnership, Radiation, Architecture, The Hepatitis C Trust, VHDL, FPGA, Trace, Linux, Risk management, Video game console

UPPSALA, Sweden, Dec. 15, 2022 /PRNewswire/ -- IAR Systems®, world leader in software and services for embedded development, and Gaisler, the fault-tolerant processor design center of CAES, are pleased to announce the start of a new partnership. IAR Systems will soon release a new version of the IAR Embedded Workbench for RISC-V. The new version will have support for NOEL-V, the RISC-V space grade processor from Gaisler. 

Key Points: 
  • IAR Systems will soon release a new version of the IAR Embedded Workbench for RISC-V.
  • For IAR Systems, this partnership is an important step into the space market, in which the NOEL-V architecture occupies a leading position.
  • "I am confident that this collaboration will greatly improve our product portfolios and will allow IAR and CAES to gain visibility across the space market."
  • Editor's Note:IAR Systems, IAR Embedded Workbench, Embedded Trust, C-Trust, C-SPY, C-RUN, C-STAT, IAR Visual State, I-jet, I-jet Trace, IAR Academy, IAR, and the logotype of IAR Systems are trademarks or registered trademarks owned by IAR Systems AB.

IAR Systems and CAES improve embedded tech in space

Retrieved on: 
Thursday, December 15, 2022
IAR, Software, CAES, IAR Systems, Ecosystem, Name, NOEL, Partnership, Radiation, Architecture, The Hepatitis C Trust, VHDL, FPGA, Trace, Linux, Risk management, Video game console

UPPSALA, Sweden, Dec. 15, 2022 /PRNewswire/ -- IAR Systems®, world leader in software and services for embedded development, and Gaisler, the fault-tolerant processor design center of CAES, are pleased to announce the start of a new partnership. IAR Systems will soon release a new version of the IAR Embedded Workbench for RISC-V. The new version will have support for NOEL-V, the RISC-V space grade processor from Gaisler. 

Key Points: 
  • IAR Systems will soon release a new version of the IAR Embedded Workbench for RISC-V.
  • For IAR Systems, this partnership is an important step into the space market, in which the NOEL-V architecture occupies a leading position.
  • "I am confident that this collaboration will greatly improve our product portfolios and will allow IAR and CAES to gain visibility across the space market."
  • Editor's Note:IAR Systems, IAR Embedded Workbench, Embedded Trust, C-Trust, C-SPY, C-RUN, C-STAT, IAR Visual State, I-jet, I-jet Trace, IAR Academy, IAR, and the logotype of IAR Systems are trademarks or registered trademarks owned by IAR Systems AB.

Odyssey Health, Inc. Completes Safety Evaluation of Cohort II for Concussion Drug

Retrieved on: 
Wednesday, June 29, 2022
Odyssey, Clinical research associate, FDA, Neurosteroid, Patient, Anxiety, Brain, Falls, Biotechnology, CEO, GLOBE, AUC, Concussion, Blood, Company, Common, Intellectual property, Oxidative stress, OTC Markets Group, Inflammation, Private Securities Litigation Reform Act, Cmax, Toxicity, Amnesia, Traffic barrier, Vital signs, Pathology, Safety, Twitter, News, MD, NOEL, EKG, Volunteering, Pharmaceutical industry

Data from Cohort II indicates that the drug was safe and well-tolerated.

Key Points: 
  • Data from Cohort II indicates that the drug was safe and well-tolerated.
  • Cohort II was unblinded and evaluated by the Safety Review Committee.
  • Cohort II included six healthy human volunteers who received one dose of PRV-002 or placebo followed by evaluations for abnormal responses.
  • After reviewing the data from Cohort II, I have strong confidence that PRV-002 will continue to show safety for this Phase I clinical trial as an option for the treatment of concussion.

Odyssey Health, Inc. Completes Safety Evaluation of Cohort I for Concussion Drug

Retrieved on: 
Wednesday, June 1, 2022
Odyssey, Vital signs, CA, VP, Drug development, Company, Intellectual property, Concussion, Anxiety, Biotechnology, Common, Safety, Traffic barrier, Toxicity, Amnesia, Pathology, Brain, News, NOEL, Inflammation, Blood, Volunteering, FDA, GLOBE, Patient, Doctor of Philosophy, Private Securities Litigation Reform Act, Technology, Cmax, Acquisition, Oxidative stress, Twitter, MD, Neurosteroid, Falls, OTC Markets Group, AUC, EKG, Pharmaceutical industry, Cohort

Odysseys trial involves administering PRV-002, the Companys novel drug to treat concussion, to healthy human subjects.

Key Points: 
  • Odysseys trial involves administering PRV-002, the Companys novel drug to treat concussion, to healthy human subjects.
  • Cohort I was unblinded and evaluated by the Safety Review Committee.
  • Cohort I included eight healthy human volunteers that received one dose of PRV-002 or placebo followed by evaluations for abnormal responses.
  • Jacob VanLandingham, Ph.D., VP of Drug Development for Odyssey Health, commented, PRV-002 appears to be well-tolerated when given intranasally.